The Institut Curie and Ipsogen Sign a Scientific Collaboration Agreement Relating to the Genomic Grade, a Molecular Diagnostic Tool for Breast Cancer
1/11/2010 8:44:30 AM
More...
|
Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting
7/10/2009 8:39:12 AM
More...
|
Ipsogen Expands its US Market Presence Through Licensing Agreement With ARUP Laboratories for the Commercialization of JAK2 Molecular Diagnostic Assays
5/4/2009 7:08:56 AM
More...
|
Ipsogen Announces the CE Marking of its "ProfileQuant(R) WT1" Kit
3/16/2009 7:43:56 AM
More...
|
Ipsogen Reinforces its Leadership in Molecular Diagnosis and Monitoring of Leukemia
1/12/2009 10:45:04 AM
More...
|
Ipsogen Launches a New Test to Determine Tumor HER2 Status and Guide Herceptin(R) Prescription in Breast Cancer
11/24/2008 8:33:39 AM
More...
|
Ipsogen Launches a New Test to Determine Tumor HER2 Status and Guide Herceptin(R) Prescription in Breast Cancer
11/24/2008 6:39:59 AM
More...
|
Ipsogen Expands Its U.S. Presence Through Licensing Agreement With Quest Diagnostics Inc. (DGX)
10/7/2008 8:16:09 AM
More...
|
Ipsogen Consolidates its Position in North America and Appoints Susan Hertzberg President
9/3/2008 6:13:48 AM
More...
|
Ipsogen Confirmation of Strong Growth Over the First Half of 2008
8/1/2008 9:53:00 AM
More...
|
|